Cardiome Pharma Corp. announced the addition of Steen Juul-Möller, M.D., Ph.D./DMSc., FESC to Cardiome's management team as Medical Director, Europe. In his capacity of Medical Director, Dr. Juul-Möller will oversee Cardiome's clinical and medical affairs activities.

Dr. Juul-Möller has held his clinical position at the Malmö University Hospital (now Skåne University Hospital) since 1980. He is a strong proponent for the rapid cardioversion of patients with recent onset atrial fibrillation (AF). Dr. Juul-Möller was responsible for changing his hospital's emergency room AF management protocol and developed an AF fast-track treatment system where patients were safely and rapidly cardioverted resulting in both patient and economic benefits.

Vernakalant was regularly used in the atrial fibrillation fast-track protocol. Since BRINAVESS(TM) was available in Sweden, clinicians at Skåne University Hospital have used it to cardiovert over 250 recent onset atrial fibrillation patients to normal sinus rhythm achieving successful cardioversion in 70% to 80% of patients, which is almost 50% higher than what was achieved in clinical trials. He has also served on the Steering Committee of both the ACT I and ACT III pivotal Phase 3 trials for vernakalant.